[Autologous blood transfusion in surgery of urologic malignant tumor].
BACKGROUND
Autologous blood transfusion has been widely endorsed, because of the adverse effects attributed to homologous blood transfusion. So we employed autologous blood transfusion to avoid homologous blood transfusion in operation of urological malignant patients. We reviewed our experience with autologous blood transfusion in 48 patients.


METHODS
A total of 48 patients underwent operation with 400 to 1,200 ml preoperative autologous blood donation, in 41 patients with administration of erythropoietin and 7 patients without erythropoietin. The details of operations are radical nephrectomy in 18 cases (2 cases were bilateral), radical nephro-ureterectomy in 2 cases, retroperitoneal lymph node dissection (RPLND) in 2 cases, radical prostatectomy in 12 cases and radical cystectomy in 14 cases.


RESULTS
The volume of surgical blood loss were 381 +/- 522 ml in nephrectomy (1,158 +/- 202 ml in bilateral case), 517 +/- 5 ml in radical nephro-ureterectomy 636 +/- 574 ml in RPLND, 665 +/- 291 ml in radical prostatectomy and 1,123 +/- 417 ml in radical cystectomy. Only three cases needed homologous blood transfusion.


CONCLUSIONS
We can avoid homologous blood transfusion in 94% of patients. Autologous blood transfusion is recommended as safe and convenient.
Kawashima
K
K
Department of Urology Ashikaga Red-cross Hospital.
Nakano
K
K
Miyamoto
S
S
Hasimoto
K
K
Shibata
Y
Y
Okazaki
H
H
Nakata
S
S
Takahashi
H
H
D000328:Adult; D000368:Aged; D001793:Blood Preservation; D001804:Blood Transfusion, Autologous / Q000379:methods*; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D014565:Urogenital Neoplasms / Q000601:surgery*; D013520:Urologic Surgical Procedures
D004921:Erythropoietin